Celyad SA: Rises on non-dilutive funding of 2.5 mln euros
06/12/2019 11:38
** U.S.-listed shares of Belgium-based drug developer
CYAD.O up ~5% at $12.69 premarket, after receiving additional
non-dilutive funding of 2.5 mln euros ($2.76 million)
** Funding includes 2.1 mln euros from SPW-Recherche of the
Walloon Region of Belgium, which will support development of
CYAD's CAR-T candidates for treatment of solid tumors
urn:newsml:reuters.com:*:nGNXc9Vk8J
** Also comprises 0.4 mln euros of non-refundable tax
incentive from Belgian Public Health Insurer
** Stock among best performers across all U.S. exchanges
** Up to Thursday's close, stock had fallen ~34% YTD
($1 = 0.9073 euros)
(Reporting by Abhishek Manikandan in Bengaluru)
((Abhishek.Manikandan@thomsonreuters.com))